{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:40:58Z","timestamp":1791229258642,"version":"4.1.0"},"reference-count":32,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024679","name":"ADVANZ PHARMA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100024679","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Cefepime\/enmetazobactam (FEP\/META) is a novel fixed-dose \u03b2-lactam\/\u03b2-lactamase inhibitor combination. The objective was to study the physicochemical stability of the approved daily dose in polypropylene syringes and elastomeric devices over a 24 or 72 h period to understand the feasibility of using FEP\/META in prolonged infusions and its use for outpatient parenteral antibiotic therapy (OPAT). Methods: Solutions of FEP\/META were prepared in 0.9% NaCl or 5% dextrose (D5W) and stored in syringes (6 g\/1.5 g\/48 mL) or silicone and polyisoprene elastomeric devices (EDs) at 6 g\/1.5 g\/120 mL and 6 g\/1.5 g\/240 mL: syringes were tested at 22\u201325 \u00b0C over a 24 h period, polyisoprene EDs at 2\u20138 \u00b0C over 72 h period, and silicone and polyisoprene EDs at 32 \u00b0C over a 24 h period. The solution was considered stable if it retained more than 90% of its initial concentration (Ci), no pH variation (\u00b11 unit), no significant visual change, and with compliant subvisual examination. Liquid Chromatography\u2013Electrospray Ionization\u2013Quadrupole Time-of-Flight\u2013Mass Spectrometry was utilized to identify intermediate degradation products. Results: At the daily dose, FEP\/META retained &gt;90% of its Ci up to 12 h in 0.9% NaCl and 24 h in D5W when stored in syringes. In silicone ED, stability was enhanced up to 24 h in D5W at all concentrations. The solution was chemically stable for 24 h when stored in polyisoprene ED in 0.9% NaCl at 2\u20138 \u00b0C. Conclusions: FEP\/META combination showed prolonged stability with physicochemical integrity up to 12\u201324 h in all containers and conditions. It appears to be stable for prolonged infusions and for OPAT.<\/jats:p>","DOI":"10.3390\/antibiotics15020114","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:41:34Z","timestamp":1769164894000},"page":"114","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["CEFEPIME\/ENMETAZOBACTAM: Physicochemical Stability of a Novel \u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combination in Syringes and Elastomeric Devices"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9426-2148","authenticated-orcid":false,"given":"Akim","family":"Chayem","sequence":"first","affiliation":[{"name":"Pharmacy Department, University Hospital, All\u00e9e du Morvan, 54511 Vand\u0153uvre-l\u00e8s-Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Quevedo","sequence":"additional","affiliation":[{"name":"Advanz Pharma UK, London EC2M 1QS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8296-0771","authenticated-orcid":false,"given":"Sandrine","family":"Cure","sequence":"additional","affiliation":[{"name":"Advanz Pharma UK, London EC2M 1QS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00eblle","family":"Jemmely","sequence":"additional","affiliation":[{"name":"Advanz Pharma UK, London EC2M 1QS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4196-0222","authenticated-orcid":false,"given":"B\u00e9atrice","family":"Demore","sequence":"additional","affiliation":[{"name":"Pharmacy Department, University Hospital, All\u00e9e du Morvan, 54511 Vand\u0153uvre-l\u00e8s-Nancy, France"},{"name":"INSPIIRE, Inserm, Universit\u00e9 de Lorraine, 54000 Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7336-1144","authenticated-orcid":false,"given":"Beatriz","family":"Esteban-Cartelle","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Ram\u00f3n y Cajal Hospital, IRYCIS, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0846-9044","authenticated-orcid":false,"given":"Brayan J.","family":"Anaya","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Food Technology, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1704-7830","authenticated-orcid":false,"given":"Gabriel A.","family":"Pe\u00f1alver","sequence":"additional","affiliation":[{"name":"Unidad de Espectrometr\u00eda de Masas, CAI T\u00e9cnicas Qu\u00edmicas, Facultad de Ciencias Qu\u00edmicas, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0475-8420","authenticated-orcid":false,"given":"Dolores R.","family":"Serrano","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Food Technology, School of Pharmacy, Complutense University of Madrid, 28040 Madrid, Spain"},{"name":"Instituto Universitario de Farmacia Industrial, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8223-3598","authenticated-orcid":false,"given":"Elise","family":"D\u2019Huart","sequence":"additional","affiliation":[{"name":"Pharmacy Department, University Hospital, All\u00e9e du Morvan, 54511 Vand\u0153uvre-l\u00e8s-Nancy, France"},{"name":"Infostab, 54170 Heillecourt, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/14787210.2023.2184347","article-title":"Continuous infusion of beta-lactam antibiotics: Narrative review of systematic reviews, and implications for outpatient parenteral antibiotic therapy","volume":"4","author":"Roberts","year":"2023","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"ref_2","first-page":"69","article-title":"Continuous or extended vs intermittent infusions of beta-lactam antibiotics in ICU patients with pneumonia: A systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Li","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13613-024-01263-9","article-title":"Prolonged versus intermittent \u03b2-lactam infusion in sepsis: A systematic review and meta-analysis of randomized controlled trials","volume":"14","author":"Zhao","year":"2024","journal-title":"Ann. Intensive Care"},{"key":"ref_4","first-page":"20499361231191877","article-title":"A review of evidence, antimicrobial stability, and feasibility considerations for OPAT continuous infusion","volume":"10","author":"Jensen","year":"2023","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"D\u2019Huart, E., Boutouha, I., Berardi, C., Vigneron, J., Demore, B., and Charmillon, A. (2025). Stability of Nine Time-Dependent Antibiotics for Outpatient Parenteral Antimicrobial Therapy (OPAT) Use. Antibiotics, 14.","DOI":"10.3390\/antibiotics14050466"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Moreal, C., Martini, L., Prataviera, F., Tascini, C., and Giuliano, S. (2025). Antibiotic Stability and Feasibility in Elastomeric Infusion Devices for OPAT: A Review of Current Evidence. J. Clin. Med., 14.","DOI":"10.3390\/jcm14082722"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/ejhpharm-2023-003855","article-title":"Systematic review of room temperature stability of key beta-lactam antibiotics for extended infusions in inpatient settings","volume":"31","author":"Jenkins","year":"2023","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1093\/ajhp\/zxac122","article-title":"Antibiotic stability in portable elastomeric infusion devices: A systematic review","volume":"79","author":"Serrano","year":"2022","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e0206423","DOI":"10.1128\/spectrum.02064-23","article-title":"Stability of meropenem in portable elastomeric infusion devices: Which protocol should be implemented in clinical practice?","volume":"12","author":"Serrano","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s40121-025-01174-7","article-title":"Stability of Ceftobiprole Medocaril in Portable Elastomeric Infusion Devices","volume":"14","author":"Anaya","year":"2025","journal-title":"Infect. Dis. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of Cefepime\/Enmetazobactam vs Piperacillin\/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"},{"key":"ref_12","unstructured":"ADVANZ Pharma (2024). EXBLIFEP 2 g\/0.5 g Powder for Concentrate for Solution for Infusion\u2014Summary of Product Characteristics (SmPC)\u2014Available Online (FDA) Label, ADVANZ Pharma."},{"key":"ref_13","unstructured":"ADVANZ Pharma (2024). EXBLIFEP 2 g\/0.5 g Powder for Concentrate for Solution for Infusion\u2014Summary of Product Characteristics (SmPC)\u2014Available Online (EMA) Exblifep, INN-Cefepime + Enmetazobactam, ADVANZ Pharma."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e00105-19","DOI":"10.1128\/AAC.00105-19","article-title":"Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent beta-Lactam-beta-Lactamase Inhibitor Combination","volume":"63","author":"Bethel","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/17425255.2024.2427310","article-title":"Cefepime\/Enmetazobactam: A microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation","volume":"21","author":"Darlow","year":"2025","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.cmi.2024.09.031","article-title":"In vitro activity of cefepime-enmetazobactam on carbapenem-resistant Gram negatives","volume":"31","author":"Bonnin","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0378-5173(97)00137-3","article-title":"Stability study of cefepime in different infusion solutions","volume":"154","author":"Guet","year":"1997","journal-title":"Int. J. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/ajhp\/56.11.1134","article-title":"Stability of cefepime hydrochloride in polypropylene syringes","volume":"56","author":"Stewart","year":"1999","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Loeuille, G., D\u2019Huart, E., Vigneron, J., Nisse, Y.-E., Beiler, B., Polo, C., Ayari, G., Sacrez, M., Demor\u00e9, B., and Charmillon, A. (2022). Stability Studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics, 11.","DOI":"10.3390\/antibiotics11040458"},{"key":"ref_20","unstructured":"Pharmaceutical Technical Procedures (2023). 2.9.19: Particulate contamination: Sub-visible particles. European Pharmacopoeia, European Directorate for the Quality of Medicines and Health Care. [11th ed.]."},{"key":"ref_21","unstructured":"Pharmaceutical Technical Procedures (2023). 2.9.20: Particulate contamination: Visible particle. European Pharmacopoeia, European Directorate for the Quality of Medicines and Health Care. [11th ed.]."},{"key":"ref_22","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration (2008). Guidance for Industry: Drug Stability Guidelines."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.pharma.2011.07.002","article-title":"Guidelines for the Practical Stability Studies of Anticancer Drugs: A European Consensus Conference","volume":"69","author":"Bardin","year":"2011","journal-title":"Ann. Pharm. Fran\u00e7aises"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2116\/analsci.26.1081","article-title":"Identification and characterization of new degradation products of cefepime dihydrochloride monohydrate drug substance during stress stability studies","volume":"26","author":"Rao","year":"2010","journal-title":"Anal. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Park, S., Park, S., Oh, S., Heo, Y., Lee, H., and Park, J. (2024). Novel Yellow Aromatic Imine Derivative Incorporating Oxazolone Moiety for Color Resist Applications. Appl. Sci., 14.","DOI":"10.3390\/app14114362"},{"key":"ref_26","unstructured":"(2025, April 25). Renapime 2g Powder for Solution for Injection\/Infusion\u2014Summary of Product Characteristics (SmPC)\u2014(Emc). Available online: https:\/\/www.medicines.org.uk\/emc\/product\/9672\/smpc\/print."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/jac\/dkg134","article-title":"Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units","volume":"51","author":"Baririan","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_28","unstructured":"(2025, July 20). N-methylpyrrolidine\u2014Data Sheet Security, Sigma Aldrich\u00ae. Available online: https:\/\/www.sigmaaldrich.com\/FR\/en\/sds\/sial\/328634?userType=anonymous."},{"key":"ref_29","unstructured":"International Conference on Harmonisation: Validation of Analytical Procedures: Text and Methodology Q2 (R1). Guide-Line 2005. Available online: http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Quality\/Q2_R1\/Step4\/Q2_R1__Guideline.pdf."},{"key":"ref_30","unstructured":"SFPC (French Society of Clinical Pharmacy), and GERPAC (Evaluation and Research Group on Protection in Controlled Atmospher) (2021, March 01). SFPC, GERPAC, Methodological Guidelines for Stability Studies of Hospital Pharmaceutical Preparations, Part I: Liquid Preparations. Available online: https:\/\/www.gerpac.eu\/IMG\/pdf\/guide_stabilite_anglais.pdf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e00859-18","DOI":"10.1128\/AAC.00859-18","article-title":"Quantification of Cefepime, Meropenem, Piperacillin, and Tazobactam in Human Plasma Using a Sensitive and Robust Liquid Chromatography-Tandem Mass Spectrometry Method, Part 1: Assay Development and Validation","volume":"62","author":"Bach","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"123079","DOI":"10.1016\/j.talanta.2021.123079","article-title":"Study of the polymerized impurities in cefotaxime sodium and cefepime by applying various chromatographic modes coupled with ion trap\/time-of-flight mass spectrometry","volume":"238","author":"Ren","year":"2022","journal-title":"Talanta"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/2\/114\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T05:18:33Z","timestamp":1769318313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/2\/114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":32,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["antibiotics15020114"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15020114","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]}}}